Announcement • Sep 24
Universal Ibogaine Inc. Announces Board Resignations Universal Ibogaine Inc. Board of directors brings together expertise in healthcare, clinical trials, financial, and legal patient safety ensuring a strong foundation to guide the company through its next phase with confidence. As part of the transition, Peter Vlahos, Constantine Buzunis, and Peter Ginakes will no longer be part of the Board of Directors and have resigned. Universal Ibogaine confirms its Board member list of Eric Hrimech, Nia Killebrew, Tony Wagner, James Duncan, Nick Karos as the organization advances toward submitting its clinical trial application to Health Canada by the end of November 2025. Announcement • Sep 04
Universal Ibogaine Inc. Announces Board Appointments, Effective August 28, 2025 Universal Ibogaine Inc. appointed two new Directors to join the Board, effective August 28, 2025, with one of the Board members filling a vacant Board position which previously arose in July 2025. The two new Board members are Nia Killebrew and Tony Wagner, who have joined the current Board members Nick Karos (CEO), James Duncan, and Dean Koumontzis. Bio information for Ms. Killebrew and Mr. Wagner are contained in UIs Management Information Circular dated July 23, 2025 (the Circular), which has been provided by UI in connection with the upcoming Annual Meeting of Shareholders (the AGM) which is to occur on September 4, 2025. Mr. Koumontzis is not standing for re-election to the Board at the AGM. Announcement • Jul 08
Universal Ibogaine Inc. Announces Resignation of Ken Cranwill as Director Universal Ibogaine Inc. advised that Ken Cranwill has resigned from the Board of Directors of the Company in order to focus on his other business ventures. Announcement • Jul 02
Universal Ibogaine Inc., Annual General Meeting, Sep 04, 2025 Universal Ibogaine Inc., Annual General Meeting, Sep 04, 2025. Announcement • Jun 08
Universal Ibogaine Inc. announced that it has received CAD 0.27 million in funding On June 6, 2024, Universal Ibogaine Inc closed the transaction. The company issued 13,500,000 common shares at a price of CAD 0.02 per share for gross proceeds of $270,000. Announcement • Apr 12
Universal Ibogaine Inc. announced that it expects to receive CAD 0.6 million in funding Universal Ibogaine Inc. announced a non-brokered private placement offering of up to 30,000,000 common shares at a price of CAD 0.02 per share, for proceeds of up to CAD 600,000 on April 12, 2024. Completion of the Offering is subject to approval by the TSX Venture Exchange. All shares issued under the Offering will be subject to a four-month hold period as required by the rules of the TSXV and Canadian Securities Laws, as well as any required hold periods under US Securities Laws for US resident purchasers. Announcement • Feb 22
Universal Ibogaine Inc. announced that it expects to receive CAD 0.8 million in funding Universal Ibogaine Inc. announced a private placement to issue up to 80,000,000 common shares at a price of CAD 0.01 per share for the gross proceeds of CAD 800,000 on February 22, 2024. The transaction is subject to the approval by the TSXV. All securities issued under the offering will be subject to a four-month hold period as required by the rules of the TSXV and Canadian Securities Laws, as well as any required hold periods under US Securities Laws for US resident purchasers. Announcement • Feb 07
Universal Ibogaine Inc. announced that it has received CAD 0.417193 million in funding On February 7, 2024, Universal Ibogaine Inc. closed the transaction. The company issued 29,219,250 common shares at an issue price of CAD 0.01 per share for gross proceeds CAD 292,192.5., resulting in an aggregate issuance of 41,719,250 common shares for gross proceeds of CAD 417,192. Announcement • Dec 21
Universal Ibogaine Inc. announced that it expects to receive CAD 1 million in funding Universal Ibogaine Inc. announced a private placement of up to 100,000,000 common shares at a price of CAD 0.01 per share for gross proceeds of up to CAD 1,000,000 on December 21, 2023. The closing of the offering, and the payment of any finders’ fees related thereto, is subject to the required approvals of the TSX Venture Exchange.
On the same day, the company issued 12,500,000 common shares for gross proceeds of up to CAD 125,000 in its first tranche. Announcement • Oct 13
Universal Ibogaine Inc Announces Board Changes Universal Ibogaine Inc. announced following changes to its Board of Directors, effective October 11, 2023: UI has appointed two new members to serve on the Company's Board of Directors (the "Board") to replace two Board members. Chief Ian Campbell and Anthony DeCristofaro have chosen to resign from the Company's Board of Directors (the "Board") in order to focus their time on family and other business opportunities. The Company thanks both Chief Campbell and Mr. DeCristofaro for their significant past guidance and commitment to helping UI in its formative stages. James Duncan - Mr. Duncan is Director of Sales & Trading with Toronto based Independent Trading Group (ITG), and has been an active trader in the Canadian markets for 40 years, covering accounts from the EU, US and Canada, both retail and institutional. James has always been active in the trading community, serving Security Traders Associations ("STA") across the country and was Chairman of the STA in the United States in 2004 as well as serving as chair of the CSTA in Canada. He founded the Bay Street Children's foundation in 2000 and currently serves as its Chairman. James and his team have raised multiple millions for children's charities in Toronto. Dr. Dean Koumontzis - Dr. Koumontzis is an expert in orthopedic surgery and sports medicine with an emphasis on treating disorders of the elbow, shoulder and knee. He also serves as Director of the Bone Health Clinic at TOCA at Banner Health. He has been an invited faculty member of prestigious institutions across the country and has also served on many orthopedic and sports medicine committees throughout his career. His abstracts, manuscripts, and articles have been published in numerous scientific journals, magazines and textbooks, and his lectures and presentations have gained national and international recognition. Dr. Koumontzis has also served as team physician and orthopedic consultant at Arizona State University and has several years of non-profit Board experience, serving in a variety of positions. He is based in Scottsdale, Arizona, and is CEO of Bone Health Solutions, which creates educational web based platforms and clinical system management solutions. Announcement • May 10
Universal Ibogaine Inc. Announces Changes to Board of Directors and Addition to Advisory Board Universal Ibogaine Inc. announced the departure of two members of its Board of Directors. Dr. Alberto Sola Agullo has decided to resign from the Board in order to focus his time on his ibogaine based addiction treatment business, Clear Sky Recovery Cancun SA de CV (Clear Sky) which operates in Cancun, Mexico. In conjunction, Robert Turner has also chosen to resign from the Board, which continues with members Ian Campbell (Chairman), Anthony Decristofaro, and Nick Karos (CEO). UI also announced of the expansion of its Advisory Board to include Amanda Zinter. Candice Wilson and Amanda Zinter the founders of WilsonZinter Enterprises Ltd., who live and work on the unceded territories of the Haisla Nation and Semiahmoo First Nation, and both work closely with Haisla Nation, Candice as the Environment Manager and Amanda as a Regulatory Consultant. WilsonZinter was formed to promote indigenous involvement in project development across Canada. Candice and Amanda have deep expertise in government, regulatory, social governance, indigenous rights, and promoting partnerships with businesses that want to demonstrate high levels of social responsibility through their involvement in the incorporation and promotion of indigenous rights and the necessity of understanding the knowledge the culture brings to environment and its connection back to oneself. Announcement • May 06
Universal Ibogaine Announces Formation of Advisory Board Universal Ibogaine Inc. announced the formation of an external Advisory Board as part of its strategic plans and mission to deliver medicalized ibogaine-centered addiction care and to undertake a planned clinical trial application process. The initial members joining the UI Advisory Board include: Melissa Lavasani Melissa Lavasani is Founder and Executive Director of Plant Medicine Coalition, a Washington DC based organization advocating for all plant medicines and their synthetic derivatives at the national, state, and local levels. Melissa proposed DC's Initiative 81, "The Entheogenic Plant and Fungus Policy Act of 2020," after entheogenic plants and fungi helped her overcome severe postpartum depression. As Chairwoman, she successfully ran the Decriminalize Nature DC, the campaign supporting the historic passage of Initiative 81. After the use of psilocybin and ayahuasca helped her reclaim her life, Melissa was motivated to change laws in the District of Columbia so that other residents would not face the same fear of investigation, arrest, and prosecution for using psychedelics to heal themselves. Marcos Moura - Marcos Moura is co-owner and Chief Development Officer of Amada Franchise Inc., a brand dedicated to enriching the lives of rapidly aging population. Marcos has helped hundreds of entrepreneurs grow businesses that allow them to live life on their terms and do work that is meaningful to them, their families, and their communities. Marcos holds an MBA from the University of Southern California (USC) and works and lives in San Clemente, CA, with his wife and three boys. Grand Chief Jerry Daniels - Grand Chief of the Southern Chiefs' Organization ("SCO"), which represents 34 Anishnaabe and Dakota communities in southern Manitoba. In January of 2020; Chief Daniels was acclaimed for a second term noting that this is the first time a Grand Chief has run unopposed in SCO's history. Chief Daniels graduated from the University of Manitoba with a Bachelor of Arts degree in economics, and he is the owner of Innovative Educational Business. Collectively First Nations are one of the key drivers of Manitoba's economy, and Chief Daniels focus is on improving the quality of life through key initiatives in the First Nations health care experience, including designing and building community care models consistent with the evolution of the children's welfare system as envisioned by southern First Nations. Grand Chief Daniels serves on boards and councils at the local, regional, and national levels. Travis Hayes Travis Hayes is the founder and CEO of Hayco Construction, a design-build general contractor with extensive experience in the development and construction of medical facilities across Canada and the USA. Travis is leader in addiction recovery in his community and has personally experienced the incredible healing powers of ibogaine, and like others who have done so, Travis is dedicated to bringing the medicalized ibogaine treatment model to the world. Announcement • Feb 07
Universal Ibogaine Inc. announced that it expects to receive CAD 5 million in funding Universal Ibogaine Inc. announced a private placement of secured guarantee convertible notes for gross proceeds of up to CAD 5 million on February 6, 2023. The notes will will bear interest of 8% payable at quarterly and have a maturity of 3 years from the closing of the transaction. On a future conversion, the holder of the notes will receive one units of company, which comprised of one common share and a one-half common share purchase warrant. The notes will have a conversion price of CAD 0.03 per common share in year 1 after closing, CAD 0.10 for year 2, and CAD 0.15 for year 3, and each whole warrant will have an escalating annual exercise price which will be CAD 0.08 if converted in year 1 after closing, and CAD 0.13 if converted in year 2, and CAD 0.18 if converted in year 3 after closing. The notes will be subordinated to the company’s existing mortgage. Closing of the transaction, and the payment of any finders fees related thereto, will be subject to the required approvals of the TSX Venture Exchange. Announcement • Jan 24
Universal Ibogaine Announces Re-Opening of the Kelburn Recovery Center Universal Ibogaine Inc. advises that it's addiction and mental health treatment clinic, the Kelburn Recovery Center ("Kelburn"), which operates near Winnipeg, Manitoba via a wholly-owned subsidiary of UI, has re-opened effective January 23, 2023. 